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Abstract
Background: The objective of this randomized prospective study was to compare the efficacy of 50 mcg
vaginal misoprostol and 3 mg dinoprostone, administered every nine hours for a maximum of three doses,
for elective induction of labor in a specific cohort of nulliparous women with an unfavorable cervix and
more than 40 weeks of gestation.
Material and Methods: One hundred and sixty-three pregnant women with more than 285 days of
gestation were recruited and analyzed. The main outcome measures were time from induction to delivery
and incidence of vaginal delivery within 12 and 24 hours. Admission rate to the neonatal intensive care unit
within 24 hours post delivery was a secondary outcome.
Results: The induction-delivery interval was significantly lower in the misoprostol group than in the
dinoprostone group (11.9 h vs. 15.5 h, p < 0.001). With misoprostol, more women delivered within 12
hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the
membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin
augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p <
0.05). Although not statistically significant, a lower Caesarean section (CS) rate was observed with
misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR)
tracings (22.5% vs. 12%, p > 0.05). From the misoprostol group more neonates were admitted to the
intensive neonatal unit, than from the dinoprostone group (13.5% vs. 4.8%, p > 0.05). One woman had an
unexplained stillbirth following the administration of one dose of dinoprostone.
Conclusions: Vaginal misoprostol, compared with dinoprostone in the regimens used, is more effective
in elective inductions of labor beyond 40 weeks of gestation. Nevertheless, this is at the expense of more
abnormal FHR tracings and more admissions to the neonatal unit, indicating that the faster approach is not
necessarily the better approach to childbirth.
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Introduction
Induction of labor is carried out for maternal and fetal
indications. One of the most common indications is pro-
longed pregnancy [1]. Recent studies have suggested that
by continuing pregnancy beyond 41 weeks, there is a sta-
tistically significant higher perinatal morbidity and mor-
tality as well as an increased risk to the mother [2,3]. Thus,
there is a growing body of evidence suggesting the elective
induction of labor at 41 weeks of gestation instead of
expectant management [4-6].
Prostaglandin analogues, dinoprostone (PGE2) and miso-
prostol (PGE1), are widely used in "induction of labor"
practice for ripening the cervix and stimulating uterine
contractions in order to achieve vaginal delivery.
Although dinoprostone has been approved by the FDA for
cervical ripening in women at or near term, misoprostol is
not currently approved for such use by the FDA, although
it has the advantages of lower cost, no need for refrigera-
tion and probably higher efficacy.
Several studies have demonstrated a higher efficacy of vag-
inally administered misoprostol compared to vaginal
dinoprostone for both cervical ripening and labor induc-
tion [7-19]. The Cochrane Pregnancy and Childbirth
Group, having reviewed 45 randomized studies, con-
cluded that vaginal misoprostol (25 to 100 mcg) was
more effective than oxytocin or dinoprostone at the usual
recommended doses for induction, but with increased
rates of uterine hyperstimulation both with and without
associated fetal heart rate (FHR) changes, as well as meco-
nium stained fluid [9]. Most of the studies included in the
previous meta-analysis used the 50 mcg dose for misopr-
ostol at a maximum interval of six hours between the
repeated doses, always resulting in higher rates of
hyperstimulation.
However, it is difficult to interpret previously published
studies comparing misoprostol with dinoprostone for
induction of labor since the majority of them are not dou-
ble-blinded [9] and they have included both complicated
and uncomplicated pregnancies, multiparous women
with nulliparous as well as a wide gestational age (GA)
range (37–42 weeks). Moreover, to reduce the risk of side
effects, one can either decrease the dose of the drug [7,19]
or prolong the dosage interval [14,15,19]. In addition,
Alexander et al. have recently shown that in prolonged
pregnancies it was not the induction per se that would
increase the risk for caesarean section (CS), but patients
related risk factors such as nulliparity and undilated cervix
and the use of epidural analgesia [20].
This study was undertaken to compare the efficacy of vag-
inal misoprostol (50 mcg) with that of vaginal dinopros-
tone (3 mg) when both are administered at an interval of
nine hours between repeated doses in a well-homoge-
nized cohort of full term pregnancies (nulliparous women
with an unfavorable cervix and without pregnancy
complications).
Material and Methods
Between March 1, 2001 and July 16, 2003, 163 women
were recruited for the study: 80 women in the misoprostol
group and 83 women in the dinoprostone group. All of
the women were recruited at Ioannina University Hospi-
tal, a tertiary referral center for high-risk pregnancies, with
about 1600 deliveries a year. The Ethics Committee of the
University of Ioannina approved the study and all partici-
pants gave their written informed consent after they had
been made aware of the purpose of the study. Although
the main indication was prolonged pregnancy, some of
the inductions were performed at the patient's request
after consultation at 40 weeks of gestation, (without any
medical indications) and only if they had not delivered by
the 285th day of gestation. A sequence from a computer-
ized random number generator was used for the alloca-
tion of patients to each group. The vaginal administration
of prostaglandins was performed by one of the resident
doctors on duty, who was not involved in managing these
women in labor or delivery. The study was double blind,
since the patients were not aware of which type of medi-
cation was used, and the deliveries were then performed
by two gynecologists blinded to the induction regimen
utilized.
Inclusion criteria were: 1) age>18 years old 2) nulliparity,
3) accurate dating of gestation, including crown rump
length (CRL) measurements in the first trimester of preg-
nancy, 4) singleton viable pregnancy, 5) gestational age ≥
285 days, 6) cephalic presentation, 7) unfavorable cervi-
cal status defined as a Bishop score (BS) of ≤5, 8) intact
membranes, 9) reactive non-stress test (NST). Exclusion
criteria were: 1) known contraindications to receiving
prostaglandins, 2) placenta previa, 3) prior uterine sur-
gery and 4) any antenatal complications.
GA was estimated by ultrasound biometry (via CRL meas-
urements in the first trimester of pregnancy) in cases
where there were more than 3 days difference from that
obtained from the last menstrual period (LMP) [21]. Uter-
ine tachysystole was defined as more than five contrac-
tions per 10 minutes, uterine hypertonus as when one
contraction lasted more than 2 minutes and hyperstimu-
lation syndrome as the presence of non-reassuring FHR
tracing combined with either tachysystole or hypertonus.
Non-reassuring FHR patterns were defined as persistent or
recurring episodes of severe variable decelerations, late
decelerations, prolonged fetal bradycardia or a combina-
tion of decreased beat-to-beat variability and a decelera-
tive pattern [22].Reproductive Biology and Endocrinology 2004, 2:70 http://www.rbej.com/content/2/1/70
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A NST to ensure the well-being of the fetus was performed
for each patient at the time of recruitment and admission
to the hospital (at least 285 days of gestation) and one
hour before the application of the prostaglandin. After the
reassessment of the cervical BS, either 50 mcg misopros-
tol, or 3 mg dinoprostone was administered in the poste-
rior vaginal fornix at 23:00 hours. The NST was repeated
(duration of two hours) after 1 h and 5 h. If the woman
was in active labor, the membranes spontaneously rup-
tured or the FHR not reassuring, the patient was trans-
ferred to the labor room. Otherwise, a second BS
evaluation was carried out the next morning at 08:00 am
(after 9 hours). If the cervix was favorable, (BS ≥ 5), the
patient was admitted to the labor ward where oxytocin
augmentation was carried out if the uterine contractions
were unsatisfactory and amniotomy was performed when
appropriate. If the cervix was still unfavorable, a second
dose of misoprostol or dinoprostone was given and the
same evaluation steps as described above were followed.
After a total of 18 h had elapsed, non-responders were
given a third dose of prostaglandin. When the third dose
was insufficient for initiating spontaneous labor, a trial of
labor was offered with oxytocin infusion and if no
progress was achieved within 6 hours (based on digital
assessment of the BS), the patient underwent a CS.
The outcome measures were divided into "obstetrical"
and "neonatal". The primary outcome measures were
time from induction to delivery and incidence of vaginal
delivery within 12 and 24 hours; the secondary outcomes
were the CS rate, the need for oxytocin augmentation, the
incidence of meconium stained amniotic fluid, the inci-
dence of uterine tachysystole, abnormal FHR tracings,
maternal morbidity, the admission to neonatal intensive
care within 24 hours and neonatal arterial cord ph, base
deficit.
Statistical analysis was performed using SPSS version 11
software. The Chi square test and Fisher's exact test were
used to analyze nominal variables in the form of fre-
quency tables. Normally distributed (Kolmogorov-Smir-
nov Test with Lilliefors correction) metric variables were
tested by the T-test for independent samples, while non-
normally distributed metric variables were analyzed by
the Mann-Whitney U test. All tests were two-tailed with a
confidence level of 95% (p < 0.05). Values are expressed
as mean ± standard error (SEM).
Results
The two groups were comparable in terms of patients' age
(28.1 years vs.27.5, p > 0.05) and indication for induction
(prolonged pregnancy 81.2% vs.78.3%, p > 0.05; social
18.8% vs. 21.7 %,) in the misoprostol and dinoprostone
groups, respectively. Gestational age (286 days,
range:285–292) and the preinduction BS (2.7 ± 0.1) in
the misoprostol group were also comparable to the dino-
prostone group (286 days, range:285–293) and (2.9 ±
0.1), respectively.
Obstetrical outcome
The induction-delivery interval was significantly shorter
(11.9 h vs. 15.6 h, p < 0.001) in the misoprostol group,
with even less need for a second or third dose (7.5% vs.
22%, p < 0.05) compared to dinoprostone. With misopr-
ostol, more women delivered within 12 h (57.5% vs.
32.5%, p < 0.01) and almost all of the women delivered
within 24 h (98.8% vs. 91.6%, p < 0.05). In addition,
spontaneous rupture of the membranes occurred more
often after the administration of misoprostol (p < 0.05)
and there was a reduced need for oxytocin augmentation
in labor: 65.8% vs. 80.7% with dinoprostone (p < 0.05).
However, uterine tachysystole (p < 0.05)) and meconium
stained amniotic fluid (p > 0.05) occurred more often in
the misoprostol group as did abnormal heart rate tracing
(22.5% vs.12%, p > 0.05) (Table 1).
In both groups, the majority of women had vaginal deliv-
ery, 92.5% with misoprostol, and 86.7% with dinopros-
tone. There was no statistically significant difference
between the two groups with regard to the CS rate (Table
2). There were no uterine ruptures or other major mater-
nal complications resulting from the use of either of the
prostaglandins. There was only one wound infection with
dinoprostone, one woman in each group had delayed dis-
charge due to persistent pyrexia and two women in the
dinoprostone group required uterine packing (insertion
of tampons within the uterine cavity) due to postpartum
bleeding.
Neonatal outcome
More neonates in the misoprostol group had first minute
Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or
needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05)
but none of the babies had birth asphyxia [23]. The mean
cord pH and the base deficit were comparable in the two
groups. No neonate had meconium aspiration syndrome.
Two neonates in the dinoprostone group had clavicle frac-
ture (Table 3). There was no statistically significant differ-
ence in the number of neonates admitted to neonatal
intensive care within 24 hours after delivery, between the
misoprostol and dinoprostone groups (6.3% vs. 3.6% p >
0.05) (Table 4).
A 28-year-old woman at 41 weeks of gestation had an
unexplained stillbirth after receiving a single dose of dino-
prostone. Seven hours later she had a cardiotocogram
without abnormal FHR patterns and regular contractions
of the uterus were evident. We decided to move her to the
labor ward and within half an hour of entry, no cardiac
activity of the fetus was found. During these 30 minutesReproductive Biology and Endocrinology 2004, 2:70 http://www.rbej.com/content/2/1/70
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Table 1: Obstetrical Outcomes
Misoprostol n = 80 (%) Dinoprostone n = 83 (%) Statistical significance
Time from induction to delivery (h ± SEM) 11.9 ± 0.6 15.6 ± 0.7 p < 0.001
Delivery < 12 h 46 (57.5%) 27 (32.5%) p < 0.01
Delivery < 24 h 79 (98.8%) 76 (91.6%) p < 0.05
Number of doses
Single dose 74 (92.4%) 65 (78.3%) p < 0.05
Second dose 6 (7.5%) 17 (20.5%)
Third dose 0 (0%) 1 (1.2%)
Required oxytocin augmentation 53(65.8%) 67(80.7%) p < 0.05
Spontaneous rupture of membranes 31 (38.8%) 17 (20.5%) p < 0.05
Meconium stained AF 15 (18.8%) 7 (9.6%) NS
Abnormal FHR 18 (22.5%) 10 (12%) NS
Uterine Tachysystole 10 (12.6%) 3 (3.6%) p < 0.05
Uterine Hyperstimulation 2 (2.5%) 1 (1.2%) NS
FHR = fetal heart rate.
AF = amniotic fluid
NS = not significant (p > 0.05)
SEM = standard error of the mean
Table 2: Mode of delivery and indications for Caesarean section
Misoprostol n = 80 (%) Dinoprostone n = 83 (%) Statistical significance
Vaginal 74 (92.5%) 72 (86.7%) NS1
Spontaneous vaginal 46 (57.5%) 52 (62.6%) NS
Vacuum assisted vaginal 28 (35.0%) 20 (24.1%) NS
Caesarean section 6 (7.5%) 11 (13.3%) NS
Nonreassuring FHR2 4 (5.0%) 6 (7.2%) NS
Failed induction 0 (0.0%) 1 (1.2%) NS
Lack of labor progress 1 (1.3%) 2 (2.4%) NS
Cephalopelvic disproportion 1 (1.3%) 2 (2.4%) NS
1NS = not significant
2FHR = fetal heart rate.
Table 3: Neonatal Outcomes
Misoprostol n = 80 (%) Dinoprostone n = 83 (%) Statistical significance
Birth weight (g) 1 3275 ± 430 3373 ± 390 NS
Perinatal death 0 1(1.2%) NS
Neonatal resuscitation 9 (11.3%) 9 (10.8%) NS
O2 Supplementation 12
Ambou ventilation 76
Intubation in labor room 11
Apgar score < 7
1 min 10 (12.5%)  5 (6.0%) NS
5 min 1 (1.3%) 0
Cord blood pH (arterial)1 7.28 ± 0.05 7.27 ± 0.05 NS
Base deficit 1 5.0 ± 2.3 5.7 ± 3.2 NS
7.01 < cord pH < 7.20 3 (3.8%) 4 (4.8%) NS
10 < base deficit < 16 1 (1.3%) 2 (2.5%) NS
Hyperbilirubinemia 2 9 (11.3%) 5 (6.0%) NS
Birth trauma 3 0 2 (2.5%) NS
1Values expressed as mean ± SD
2Excluding pathological causes of icterus
3Both were clavicle fracturesReproductive Biology and Endocrinology 2004, 2:70 http://www.rbej.com/content/2/1/70
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FHR monitoring had been discontinued, as it was not
included in the study design. We decided to let her
attempt vaginal delivery. An amniotomy was performed
and the amniotic fluid was found to be clear and a vaginal
delivery was achieved within 6 hours. Direct examination
of the fetus, the placenta and the umbilical cord (UC)
showed only a thin UC with excess twisting around its
axis. The anatomopathology examination of the fetus
revealed no abnormality except a microscopically
decreased Wharton's jelly.
Discussion
Nowadays, induction of labor is more widely used than
ever before [24,25]. Recent studies have shown that this
increase is mainly due to a rise of inductions for marginal
or elective reasons. The common indications are elective
induction and postdate pregnancy often applied to gesta-
tions of 40 to 41 weeks [1,25]. Mongelli et al. have also
shown that for the detection of post-maturity there is no
advantage in using menstrual dates when ultrasound
biometry is available [26]. Women may experience dis-
tress when labor has not started by the expected date [27]
and obstetricians have to withstand pressure from these
patients as well as the temptation to use prostaglandins
earlier. Appropriate evaluation of the pregnancy and con-
sultation with such patients will lead to the correct selec-
tion of those who will benefit most from a labor
induction, thus eliminating the risk of post-maturity to
the fetus without inducing fetal distress during labor.
To the best of our knowledge, the present study is the only
one that compares misoprostol and dinoprostone in such
well-homogenized groups. All of the women were nul-
liparous with intact membranes and at more than forty
weeks' gestation with no antenatal complications and all
had an unfavorable cervix. In these carefully selected
patients, misoprostol at the dose used not only shortened
the time between induction and delivery (11.9 vs. 15.6 h),
but it also was significantly more effective than dinopros-
tone. The positive point was that this result was achieved
with a very low CS rate even in the dinoprostone group,
(7.5%, and 13.3%), respectively. A difference of 5% in
favor of misoprostol, although not statistically significant,
might have clinical importance in terms of patient health
and cost effectiveness. Although in the recent large meta-
analysis [9] published by the Cochrane Library, the CS
rates were inconsistent, they tended to be lower with mis-
oprostol; an earlier study by Sanchez-Ramos et al. found a
statistically significant difference in favor of misoprostol
[28]. In addition, our results for this GA window are reas-
Table 4: Admission to Neonatal Intensive Care Unit
N (%) DA1 Delivery2 Indication Diagnosis HDs3
Within 24 hours
Misoprostol† 5 (6.3%) 01 VVD Rule out infection Elevated CRP4WBC5 07
01 VVD Respiratory distress Respiratory infection 11
01 CS Rule out asphyxia Infection 10
01 SVD Respiratory distress Work up for infection 03
01 VVD Respiratory distress Work up for infection 04
Dinoprostone† 3 (3.6%) 01 VVD Respiratory distress Atelectasis 06
01 SVD Rule out asphyxia Infection 10
01 SVD Respiratory distress Respiratory infection 10
After 24 hours
Misoprostol† 6 (7.2%) 02 VVD Rule out infection WBC in CSF6 10
07 VVD Hyperbilirubinemia Urinary infection 07
04 SVD Hyperbilirubinemia Icterus 04
08 SVD Infection Respiratory infection 10
03 SVD Feeding difficulty WBC in CSF 20
05 CS Hyperbilirubinemia Icterus 04
Dinoprostone† 1 (1.2%) 17 SVD Fever WBC in CSF 15
1 DA = day of admittance
2 SVD = Spontaneous Vaginal Delivery, VVD = vacuum assisted vaginal delivery, CS = Caesarean section
3 HDs = hospitalization days
4 CRP = C-reactive protein
5 WBC = white blood cell
6 CSF = cerebrospinal fluid
† not significant (p > 0.05)Reproductive Biology and Endocrinology 2004, 2:70 http://www.rbej.com/content/2/1/70
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suring with regard to concerns that have been raised from
previous retrospective studies reporting an increased risk
of Caesarean delivery in nulliparous women when elec-
tive inductions are performed [29,30].
Even though misoprostol improves the kinetics of labor
during induction in a more efficient way than dinopros-
tone, concerns persist with respect to intrapartum fetal
"wellbeing". In order to avoid uterine hyperstimulation
and abnormal FHR tracings, we used for first time in the
literature, a 9 h interval between the prostaglandin doses.
Although we indeed achieved a low rate of uterine hyper-
stimulation syndrome (2.5% with misoprostol and 1.2%
with dinoprostone, respectively), we still noticed a trend
towards a high rate of abnormal FHR tracings during
induction with misoprostol. Our findings, in accordance
with the previous Cochrane metanalysis [9], showed that
with misoprostol there was an increased probability of
meconium staining of amniotic fluid as well as of uterine
tachysystole and of abnormal FHR tracings. In the
misoprostol group, the majority of women also
underwent either a CS or a vacuum operative delivery due
to non-reassuring FHR. If neonatal outcomes such as neo-
natal resuscitation, low Apgar score in the first minute and
admittance to the neonatal unit within the first 24 hours
(none of the above were statistically significant but they
were more frequent with misoprostol) are taken into
account, misoprostol may increase these complications in
labor. Thus, although our sample size cannot determine
safety, misoprostol use is associated with a higher chance
of admittance to the neonatal unit within 24 hours even
in the absence of asphyxia. This evidence indicates that
the faster approach to childbirth is not necessarily the bet-
ter one.
Attempting an explanation to the aforementioned side
effects of misoprostol use and taking into account other
reports [9,31,32], it appears that the increase in clinically
relevant adverse effects is not only misoprostol related but
it may be dose dependent. Lyons et al. have recently
shown in term pregnant rats that a higher dose of misopr-
ostol is needed to induce PGE2 secretion in the cervix than
in the myometrium, and furthermore that EP3 receptors
(prostaglandin E2 receptors) are differentially expressed
in the myometrium (increased) than in the cervix (unal-
tered) in response to misoprostol [33]. The above findings
indicate that misoprostol not only acts better on the myo-
metrium than on the cervix, but an even higher dose is
needed in order to ripen the cervix. Thus, it seems reason-
able that increasing the interval between repeated misopr-
ostol doses should reduce the risk of an asynchrony
between a well or even hyper-stimulated uterus and a still
not efficiently ripened cervix. Misoprostol probably has a
large inter-patient variability in terms of pharmacokinet-
ics, but it is also probable that the 50 mcg dosage may
induce asynchrony between immature cervix effacement
and uterine contractions, resulting in a more rapid but
also more "stressful" labor. Based on these findings, we
would propose, in future, a slight modification of the mis-
oprostol protocol used in this study. An initial lower dose
of misoprostol (20–25 mcg), followed by 50 mcg should
be considered in trying to achieve priming of the cervix
without inducing such high uterine contractility and neo-
natal complications. Indeed, in a recent study comparing
25 mcg misoprostol with 1 mg dinoprostone adminis-
tered vaginally every four hours, the admission rate to
neonatal intensive unit was significantly lower in the mis-
oprostol group [34].
It still has to be mentioned that in many of our partici-
pants, the vertex was not engaged in the pelvic inlet on the
day of admittance and this should have been included as
an independent risk factor in the initial study design. The
exact cause of the stillbirth in the dinoprostone group
remains unclear, emphasizing thus, the need for continu-
ous FHR monitoring during labor induction if regular
uterine contractions persist [35,36].
Conclusions
To conclude, 50 mcg misoprostol at a 9 h interval is more
highly effective in promoting cervical ripening and in
inducing labor, compared to dinoprostone. However, cer-
tain aspects concerning fetal well being during labor
induction remain questionable. Larger prospective studies
comparing elective induction to expectant management
after a completed 40-week gestation (on the basis of early
ultrasound biometry) might reveal a subgroup of women,
such as nulliparous with an unfavorable cervix, who
might benefit from an elective induction, preferably with
a 25 mcg misoprostol initial dose.
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